Wong Raymond L M, Gangwani R A, Yu Lester W H, Lai Jimmy S M
Eye Institute, The University of Hong Kong, Room 301, Level 3, Block B, 100 Cyberport Road, Cyberport 4, Hong Kong.
J Ophthalmol. 2012;2012:831502. doi: 10.1155/2012/831502. Epub 2012 Sep 6.
Purpose. To review the newer treatments for bacterial keratitis. Data Sources. PubMed literature search up to April 2012. Study Selection. Key words used for literature search: "infectious keratitis", "microbial keratitis", "infective keratitis", "new treatments for infectious keratitis", "fourth generation fluoroquinolones", "moxifloxacin", "gatifloxacin", "collagen cross-linking", and "photodynamic therapy". Data Extraction. Over 2400 articles were retrieved. Large scale studies or publications at more recent dates were selected. Data Synthesis. Broad spectrum antibiotics have been the main stay of treatment for bacterial keratitis but with the emergence of bacterial resistance; there is a need for newer antimicrobial agents and treatment methods. Fourth-generation fluoroquinolones and corneal collagen cross-linking are amongst the new treatments. In vitro studies and prospective clinical trials have shown that fourth-generation fluoroquinolones are better than the older generation fluoroquinolones and are as potent as combined fortified antibiotics against common pathogens that cause bacterial keratitis. Collagen cross-linking was shown to improve healing of infectious corneal ulcer in treatment-resistant cases or as an adjunct to antibiotics treatment. Conclusion. Fourth-generation fluoroquinolones are good alternatives to standard treatment of bacterial keratitis using combined fortified topical antibiotics. Collagen cross-linking may be considered in treatment-resistant infectious keratitis or as an adjunct to antibiotics therapy.
目的。回顾细菌性角膜炎的新型治疗方法。数据来源。截至2012年4月的PubMed文献检索。研究选择。文献检索使用的关键词:“感染性角膜炎”、“微生物性角膜炎”、“感染性角膜炎”、“感染性角膜炎的新治疗方法”、“第四代氟喹诺酮类药物”、“莫西沙星”、“加替沙星”、“胶原交联”和“光动力疗法”。数据提取。检索到2400多篇文章。选择近期的大规模研究或出版物。数据综合。广谱抗生素一直是细菌性角膜炎治疗的主要手段,但随着细菌耐药性的出现,需要更新的抗菌药物和治疗方法。第四代氟喹诺酮类药物和角膜胶原交联是新型治疗方法之一。体外研究和前瞻性临床试验表明,第四代氟喹诺酮类药物比老一代氟喹诺酮类药物更好,并且在对抗引起细菌性角膜炎的常见病原体方面与联合强化抗生素一样有效。胶原交联在难治性病例中或作为抗生素治疗的辅助手段时,可改善感染性角膜溃疡的愈合。结论。第四代氟喹诺酮类药物是使用联合强化局部抗生素治疗细菌性角膜炎的标准治疗方法的良好替代方案。在难治性感染性角膜炎或作为抗生素治疗的辅助手段时,可考虑胶原交联。